Accompanying DCIS in breast cancer patients with invasive ductal carcinoma is predictive of improved local recurrence-free survival

Breast

Volumn 23, Issue 4, 2014, Pages 346-351

  Dieterich, M ^a   Hartwig, F ^a   Stubert, J ^a   Klocking S ^a   Kundt, G ^a   Stengel, B ^b   Reimer, T ^a   Gerber, B ^a  

^a UNIVERSITY OF ROSTOCK   (Germany)

^b Suedstadt Hospital of Rostock   (Germany)

Author keywords

Accompanying DCIS; Breast cancer; DCIS; Invasive carcinoma; Local recurrence; Prognosis

Indexed keywords

AROMATASE INHIBITOR; TAMOXIFEN;

ADJUVANT CHEMORADIOTHERAPY; ADULT; AGE; AGED; ARTICLE; BONE METASTASIS; BREAST CANCER; BREAST CARCINOMA; CANCER GRADING; CANCER PATIENT; CANCER SIZE; CANCER STAGING; CONTROLLED STUDY; DISTANT METASTASIS; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; INTRADUCTAL CARCINOMA; LIVER METASTASIS; LOCAL RECURRENCE FREE SURVIVAL; LUNG METASTASIS; LYMPH NODE; LYMPH NODE METASTASIS; LYMPH VESSEL METASTASIS; MAJOR CLINICAL STUDY; MASTECTOMY; PRIORITY JOURNAL; PROGESTERONE RECEPTOR POSITIVE BREAST CANCER; SKIN METASTASIS; SURVIVAL RATE; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, INTRADUCTAL, NONINFILTRATING; COHORT ANALYSIS; DISEASE FREE SURVIVAL; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASMS, MULTIPLE PRIMARY; PATHOLOGY; PROGNOSIS; RETROSPECTIVE STUDY; TUMOR RECURRENCE; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, INTRADUCTAL, NONINFILTRATING; COHORT STUDIES; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MASTECTOMY; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS, MULTIPLE PRIMARY; PROGNOSIS; RETROSPECTIVE STUDIES;

EID: 84902546065     PISSN: 09609776     EISSN: 15323080     Source Type: Journal    
DOI: 10.1016/j.breast.2014.01.015     Document Type: Article

References (40)

1. Pinder S.E., Ellis I.O. The diagnosis and management of pre-invasive breast disease: ductal carcinoma in situ (DCIS) and atypical ductal hyperplasia (ADH) - current definitions and classification. Breast Cancer Res 2003, 5(5):254-257.
2. Wong H., Lau S., Yau T., Cheung P., Epstein R.J. Presence of an in situ component is associated with reduced biological aggressiveness of size-matched invasive breast cancer. Br J Cancer 2010 Apr 27, 102(9):1391-1396.
3. Yiu C.C., Loo W.T., Lam C.K., Chow L.W. Presence of extensive intraductal component in patients undergoing breast conservative surgery predicts presence of residual disease in subsequent completion mastectomy. Chin Med J (Engl) 2009 Apr 20, 122(8):900-905.
4. Holland R., Connolly J.L., Gelman R., Mravunac M., Hendriks J.H., Verbeek A.L., et al. The presence of an extensive intraductal component following a limited excision correlates with prominent residual disease in the remainder of the breast. J Clin Oncol 1990 Jan, 8(1):113-118.
5. Singletary S.E. A working model for the time sequence of genetic changes in breast tumorigenesis. J Am Coll Surg 2002 Feb, 194(2):202-216.
6. Alexe G., Dalgin G.S., Ganesan S., Delisi C., Bhanot G. Analysis of breast cancer progression using principal component analysis and clustering. J Biosci 2007 Aug, 32(5):1027-1039.
7. Aubele M., Mattis A., Zitzelsberger H., Walch A., Kremer M., Welzl G., et al. Extensive ductal carcinoma In situ with small foci of invasive ductal carcinoma: evidence of genetic resemblance by CGH. Int J Cancer 2000 Jan 1, 85(1):82-86.
8. Kuerer H.M., Albarracin C.T., Yang W.T., Cardiff R.D., Brewster A.M., Symmans W.F., et al. Ductal carcinoma in situ: state of the science and roadmap to advance the field. J Clin Oncol 2009 Jan 10, 27(2):279-288.
9. Castro N.P., Osorio C.A., Torres C., Bastos E.P., Mourao-Neto M., Soares F.A., et al. Evidence that molecular changes in cells occur before morphological alterations during the progression of breast ductal carcinoma. Breast Cancer Res 2008, 10(5):R87.
10. Iakovlev V.V., Arneson N.C., Wong V., Wang C., Leung S., Iakovleva G., et al. Genomic differences between pure ductal carcinoma in situ of the breast and that associated with invasive disease: a calibrated aCGH study. Clin Cancer Res 2008 Jul 15, 14(14):4446-4454.
11. Farabegoli F., Champeme M.H., Bieche I., Santini D., Ceccarelli C., Derenzini M., et al. Genetic pathways in the evolution of breast ductal carcinoma in situ. J Pathol 2002 Mar, 196(3):280-286.
12. Patla A., Rudnicka-Sosin L., Pawlega J., Stachura J. Prognostic significance of selected immunohistochemical parameters in patients with invasive breast carcinoma concomitant with ductal carcinoma in situ. Pol J Pathol 2002, 53(1):25-27.
13. Porter D., Lahti-Domenici J., Keshaviah A., Bae Y.K., Argani P., Marks J., et al. Molecular markers in ductal carcinoma in situ of the breast. Mol Cancer Res 2003 Mar, 1(5):362-375.
14. Ma X.J., Salunga R., Tuggle J.T., Gaudet J., Enright E., McQuary P., et al. Gene expression profiles of human breast cancer progression. Proc Natl Acad Sci U S A 2003 May 13, 100(10):5974-5979.
15. Schnitt S.J. The transition from ductal carcinoma in situ to invasive breast cancer: the other side of the coin. Breast Cancer Res 2009, 11(1):101.
16. Lakhani S.R., O'Hare M.J. The mammary myoepithelial cell - Cinderella or ugly sister?. Breast Cancer Res 2001, 3(1):1-4.
17. Barsky S.H., Karlin N.J. Mechanisms of disease: breast tumor pathogenesis and the role of the myoepithelial cell. Nat Clin Pract Oncol 2006 Mar, 3(3):138-151.
18. Black M.M., Zachrau R.E., Hankey B.F., Feuer E.J. Prognostic significance of in situ carcinoma associated with invasive breast carcinoma. A natural experiment in cancer immunology?. Cancer 1996 Aug 15, 78(4):778-788.
19. Singletary S.E., Allred C., Ashley P., Bassett L.W., Berry D., Bland K.I., et al. Revision of the American Joint Committee on Cancer staging system for breast cancer. J Clin Oncol 2002 Sep 1, 20(17):3628-3636.
20. Voduc K.D., Cheang M.C., Tyldesley S., Gelmon K., Nielsen T.O., Kennecke H. Breast cancer subtypes and the risk of local and regional relapse. J Clin Oncol 2010 Apr 1, 28(10):1684-1691.
21. Goldhirsch A., Wood W.C., Coates A.S., Gelber R.D., Thurlimann B., Senn H.J. Strategies for subtypes - dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol 2011 Aug, 22(8):1736-1747.
22. Reimer T., Fietkau R., Markmann S., Stachs A., Gerber B. How important is the axillary nodal status for adjuvant treatment decisions at a breast cancer multidisciplinary tumor board? A survival analysis. Ann Surg Oncol 2008 Feb, 15(2):472-477.
23. Schmidt M., Fasching P.A., Beckmann M.W., Kölbl H. Biomarkers in breast cancer - an update. Geburtsh Frauenheilk 27.09 2012, 72(09):819-832.
24. Nielsen T.O., Hsu F.D., Jensen K., Cheang M., Karaca G., Hu Z., et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res 2004 Aug 15, 10(16):5367-5374.
25. Cheang M.C., Chia S.K., Voduc D., Gao D., Leung S., Snider J., et al. Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst 2009 May 20, 101(10):736-750.
26. Mylonas I., Makovitzky J., Jeschke U., Briese V., Friese K., Gerber B. Expression of Her2/neu, steroid receptors (ER and PR), Ki67 and p53 in invasive mammary ductal carcinoma associated with ductal carcinoma in situ (DCIS) versus invasive breast cancer alone. Anticancer Res 2005 May-Jun, 25(3A):1719-1723.
27. Buerger H., Mommers E.C., Littmann R., Simon R., Diallo R., Poremba C., et al. Ductal invasive G2 and G3 carcinomas of the breast are the end stages of at least two different lines of genetic evolution. J Pathol 2001 Jun, 194(2):165-170.
28. Lee S., Stewart S., Nagtegaal I., Luo J., Wu Y., Colditz G., et al. Differentially expressed genes regulating the progression of ductal carcinoma in situ to invasive breast cancer. Cancer Res 2012 Sep 1, 72(17):4574-4586.
29. Gao Y., Niu Y., Wang X., Wei L., Lu S. Genetic changes at specific stages of breast cancer progression detected by comparative genomic hybridization. J Mol Med (Berl) 2009 Feb, 87(2):145-152.
30. Bombonati A., Sgroi D.C. The molecular pathology of breast cancer progression. J Pathol 2011 Jan, 223(2):307-317.
31. Lakhani S.R. The transition from hyperplasia to invasive carcinoma of the breast. J Pathol 1999 Feb, 187(3):272-278.
32. Menard S., Fortis S., Castiglioni F., Agresti R., Balsari A. HER2 as a prognostic factor in breast cancer. Oncology 2001, 61:67-72. Suppl. 2.
33. Logullo A.F., Godoy A.B., Mourao-Neto M., Simpson A.J., Nishimoto I.N., Brentani M.M. Presence of ductal carcinoma in situ confers an improved prognosis for patients with T1N0M0 invasive breast carcinoma. Braz J Med Biol Res 2002 Aug, 35(8):913-919.
34. Matsukuma A., Enjoji M., Toyoshima S. Ductal carcinoma of the breast. an analysis of proportions of intraductal and invasive components. Pathol Res Pract 1991 Jan, 187(1):62-67.
35. Chagpar A.B., McMasters K.M., Sahoo S., Edwards M.J. Does ductal carcinoma in situ accompanying invasive carcinoma affect prognosis?. Surgery 2009 Oct, 146(4):561-567. discussion 7-8.
36. Rowell N.P. Radiotherapy to the chest wall following mastectomy for node-negative breast cancer: a systematic review. Radiother Oncol 2009 Apr, 91(1):23-32.
37. Killander F., Anderson H., Ryden S., Moller T., Hafstrom L.O., Malmstrom P. Efficient reduction of loco-regional recurrences but no effect on mortality twenty years after postmastectomy radiation in premenopausal women with stage II breast cancer - a randomized trial from the South Sweden Breast Cancer Group. Breast 2009 Oct, 18(5):309-315.
38. EBCTCG EBCTCG Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005 May 14-20, 365(9472):1687-1717.
39. Karlsson P., Cole B.F., Chua B.H., Price K.N., Lindtner J., Collins J.P., et al. Patterns and risk factors for locoregional failures after mastectomy for breast cancer: an International Breast Cancer Study Group report. Ann Oncol 2012 Nov, 23(11):2852-2858.
40. Botteri E., Gentilini O., Rotmensz N., Veronesi P., Ratini S., Fraga-Guedes C., et al. Mastectomy without radiotherapy: outcome analysis after 10 years of follow-up in a single institution. Breast Cancer Res Treat 2012 Aug, 134(3):1221-1228.